Brought to you by 
MedImmune acquires Aviron
12 Dec 2001
Executive Summary
MedImmune (immune and infectious disease therapeutics) will acquire Aviron (vaccines) in a stock swap valued at about $1.5bn. For each share of Aviron, shareholders will receive 1.075 MedImmune shares (valued at $48.17, a 34% premium to Aviron's market average).
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MedImmune acquires Aviron
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice